S&P 500   3,159.38 (+0.56%)
DOW   28,043.76 (+0.47%)
QQQ   205.90 (+0.45%)
AAPL   270.10 (-0.25%)
FB   200.91 (-0.67%)
MSFT   152.06 (+0.24%)
GOOGL   1,344.86 (+0.05%)
AMZN   1,752.79 (+0.23%)
MU   50.71 (+2.94%)
GE   11.38 (+3.64%)
TSLA   359.61 (+1.96%)
T   38.43 (+0.68%)
NFLX   296.49 (-0.82%)
BAC   34.40 (+2.26%)
GILD   67.61 (-0.25%)
DIS   147.50 (-0.06%)
S&P 500   3,159.38 (+0.56%)
DOW   28,043.76 (+0.47%)
QQQ   205.90 (+0.45%)
AAPL   270.10 (-0.25%)
FB   200.91 (-0.67%)
MSFT   152.06 (+0.24%)
GOOGL   1,344.86 (+0.05%)
AMZN   1,752.79 (+0.23%)
MU   50.71 (+2.94%)
GE   11.38 (+3.64%)
TSLA   359.61 (+1.96%)
T   38.43 (+0.68%)
NFLX   296.49 (-0.82%)
BAC   34.40 (+2.26%)
GILD   67.61 (-0.25%)
DIS   147.50 (-0.06%)
S&P 500   3,159.38 (+0.56%)
DOW   28,043.76 (+0.47%)
QQQ   205.90 (+0.45%)
AAPL   270.10 (-0.25%)
FB   200.91 (-0.67%)
MSFT   152.06 (+0.24%)
GOOGL   1,344.86 (+0.05%)
AMZN   1,752.79 (+0.23%)
MU   50.71 (+2.94%)
GE   11.38 (+3.64%)
TSLA   359.61 (+1.96%)
T   38.43 (+0.68%)
NFLX   296.49 (-0.82%)
BAC   34.40 (+2.26%)
GILD   67.61 (-0.25%)
DIS   147.50 (-0.06%)
S&P 500   3,159.38 (+0.56%)
DOW   28,043.76 (+0.47%)
QQQ   205.90 (+0.45%)
AAPL   270.10 (-0.25%)
FB   200.91 (-0.67%)
MSFT   152.06 (+0.24%)
GOOGL   1,344.86 (+0.05%)
AMZN   1,752.79 (+0.23%)
MU   50.71 (+2.94%)
GE   11.38 (+3.64%)
TSLA   359.61 (+1.96%)
T   38.43 (+0.68%)
NFLX   296.49 (-0.82%)
BAC   34.40 (+2.26%)
GILD   67.61 (-0.25%)
DIS   147.50 (-0.06%)
Log in

NASDAQ:RUBY - Rubius Therapeutics Stock Price, Forecast & News

$13.01
+0.17 (+1.32 %)
(As of 12/12/2019 01:26 PM ET)
Today's Range
$12.50
Now: $13.01
$13.38
50-Day Range
$7.26
MA: $9.14
$12.78
52-Week Range
$6.96
Now: $13.01
$20.44
Volume11,508 shs
Average Volume449,717 shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.97 per share

Profitability

Net Income$-89,190,000.00

Miscellaneous

Employees142
Market Cap$1.04 billion
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.


Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) issued its quarterly earnings results on Thursday, November, 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.06. During the same quarter in the prior year, the business posted ($0.42) earnings per share. View Rubius Therapeutics' Earnings History.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Rubius Therapeutics.

What price target have analysts set for RUBY?

5 analysts have issued twelve-month price objectives for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $40.00. On average, they anticipate Rubius Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 93.6% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

What is the consensus analysts' recommendation for Rubius Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.

What are Wall Street analysts saying about Rubius Therapeutics stock?

Here are some recent quotes from research analysts about Rubius Therapeutics stock:
  • 1. According to Zacks Investment Research, "Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. " (11/20/2019)
  • 2. HC Wainwright analysts commented, "We have currently only assigned value to RTX-134 in PKU and RTX-240 in NSCLC. Our price target of $40/share is based on an equally-weighted composite of: (a) $40.7/share, as a 30x multiple of taxed and diluted $21.95 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $39.4/share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (6/26/2019)

Has Rubius Therapeutics been receiving favorable news coverage?

News stories about RUBY stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rubius Therapeutics earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Rubius Therapeutics.

Are investors shorting Rubius Therapeutics?

Rubius Therapeutics saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 9,410,000 shares, a decrease of 7.3% from the November 14th total of 10,150,000 shares. Based on an average trading volume of 354,800 shares, the days-to-cover ratio is currently 26.5 days. Approximately 31.9% of the company's stock are sold short. View Rubius Therapeutics' Current Options Chain.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the folowing people:
  • Mr. David R. Epstein, Exec. Chairman (Age 57)
  • Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
  • Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (1.83%), Nikko Asset Management Americas Inc. (1.83%), State Street Corp (0.78%), Millennium Management LLC (0.07%), California Public Employees Retirement System (0.06%) and Barclays PLC (0.03%). Company insiders that own Rubius Therapeutics stock include Christopher L Carpenter, Francis M Cuss, Robert Langer and Torben Straight Nissen. View Institutional Ownership Trends for Rubius Therapeutics.

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, Robert Langer and Torben Straight Nissen. View Insider Buying and Selling for Rubius Therapeutics.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., SG Americas Securities LLC, State Street Corp, Millennium Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Rubius Therapeutics.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $12.91.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $1.03 billion. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is http://www.rubiustx.com/.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]


MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: 12b-1 Fees

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel